Dirk Sauer
Direktor/Vorstandsmitglied bei Iconic Therapeutics, Inc.
Vermögen: 7 512 $ am 30.04.2024
Profil
Dirk Sauer is currently a Director at Iconic Therapeutics, Inc. He was previously the Head of Ophthalmology & Global Development Unit at Novartis International AG from 2011 to 2021.
Prior to that, he served as an Independent Director at Graybug Vision, Inc. Dr. Sauer obtained his undergraduate degree from the University of Münster and his doctorate from the Philipps University of Marburg.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CALCIMEDICA, INC.
0,01% | 23.03.2023 | 1 420 ( 0,01% ) | 7 512 $ | 30.04.2024 |
Aktive Positionen von Dirk Sauer
| Unternehmen | Position | Beginn |
|---|---|---|
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Direktor/Vorstandsmitglied | 20.04.2021 |
Ehemalige bekannte Positionen von Dirk Sauer
| Unternehmen | Position | Ende |
|---|---|---|
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01.03.2021 |
| CALCIMEDICA, INC. | Direktor/Vorstandsmitglied | - |
Ausbildung von Dirk Sauer
| University of Münster | Undergraduate Degree |
| Philipps University of Marburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 3 |
|---|---|
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Graybug Vision, Inc. develops ophthalmic drugs. It focus on developing drug delivery therapies for the treatment of eye diseases such as age-related macular degeneration and glaucoma. The company was founded by Justin S. Hanes, Peter John McDonnell, Christy Wyskiel and Peter A. Campochiaro in May 2011 and is headquartered in Redwood City, CA. | Health Technology |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
